IL6 and obesity disorder: When restricted to obesity-associated cancers, IL-6 remained significantly associated with increased risk of cancer mortality (HR: 3.33, 95% CI: 1.61–6.87), but none of the other biomarkers remained significant in adjusted models (Table 4).